• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cosmos Health Inc. - Common Stock (NQ: COSM )

    0.6225 -0.0372 (-5.64%)
    Streaming Delayed Price Updated: 2:42 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 79,262
    Open 0.6389
    Bid (Size) 0.6228 (13)
    Ask (Size) 0.6500 (10)
    Prev. Close 0.6597
    Today's Range 0.6110 - 0.6550
    52wk Range 0.4677 - 1.650
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
    Via ACCESSWIRE
    Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000
    Via ACCESSWIRE

    Performance

    YTD
    -54.56%
    -54.56%
    1 Month
    -16.98%
    -16.98%
    3 Month
    -31.98%
    -31.98%
    6 Month
    -3.49%
    -3.49%
    1 Year
    -55.22%
    -55.22%

    More News

    Read More
    Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price
    Via ACCESSWIRE
    Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets
    Via ACCESSWIRE
    Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M QoQ
    Via ACCESSWIRE
    Why Cosmos Health Stock Is Moving Higher Wednesday
    Via Benzinga
    COSM Stock Earnings: Cosmos Health Reported Results for Q2 2024
    Via InvestorPlace
    Cosmos Health Issues Letter to Shareholders
    Via ACCESSWIRE
    Cosmos Health’s Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%
    Via ACCESSWIRE
    How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
    Via News Direct
    Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands
    Via ACCESSWIRE
    Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins
    Via ACCESSWIRE
    Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits
    Via ACCESSWIRE
    Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion
    Via ACCESSWIRE
    Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments
    Via ACCESSWIRE
    Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price
    Via ACCESSWIRE
    Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar
    Via ACCESSWIRE
    EXCLUSIVE: Virax Biolabs Inks Distribution Pact For Mpox Diagnostic Kits In Europe And Middle East
    Via Benzinga
    Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements
    Via ACCESSWIRE
    Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE
    Via ACCESSWIRE
    Cosmos Health Holds EU Distribution Rights for Virax Biolabs’ Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits
    Via ACCESSWIRE
    Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs. H1 2023
    Via ACCESSWIRE
    Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit
    Via ACCESSWIRE
    Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market
    Via ACCESSWIRE
    Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share
    Via ACCESSWIRE
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.